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1. INTRODUCTION 2. MATERIALS AND METHODS 
Annexin Y beIoJlgs to a lar& pro&in farnil:, she mem- 
hers of w&h exhibit CaGGGlegendent binding to 
phospho(ipid. This characteristic is the basis for the 
potent anti-phospholipase and anticoagulant functions 
of the annexins [l]. Because of its therapeutic potential 
as an anticoagulant or anti-intlammatory agent, the 
physical properties of anncxin Y have been studied in 
some detail. Like most annexins, it has an internal 4- 
fold repeat of a hydrophobic 70 amino acid domain 
which is flanked by short amino- and carboxy-terminal 
regions [2]. Analysis of the 3D structure of the protein 
‘? f& ~~~~\%‘~~~C :& :a 2 -synm&%%!r -nnJRullfG*b>s %%&3 
5 atoms ofcalcium and has characteristics of membrane 
channel-forming proteins [3,4]. Despite detailed investi- 
gation of its properties and structl:re, the true function 
of annexin V is unknown. 
Annexin V is widely distributed. Very low levels of 
annexin V have been detected in plasma, however, the 
protein is abundant in cultured endothelial cells, in sol- 
uble extracts of many human tissues, and appears to be 
ubiquitous [S,S]. This type of distribution raises the pos- 
sibility that the protein functions at a cellular level. 
Analysis of the subcellular localization of annexin V 
may therefore help to elucidate its physiological func- 
tion. We have. studied the subcellular localization of 
annexin V in primary human endothelial cells, as well 
as in the HES, HeLa and A549 cell lines. The protein 
is located within the cell and appears in the cytoplasm 
and nucleolus. 
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Annexin Y -pl’irs purified io homoger& horn humnn phwAa 3s 
described 171. The preparation contained a sin& 35 kDa protein, as 
asscsscd by SDS-PAGE followed by silver suining (Bio-Rad). lodina- 
lion [B] of the preparation followed by SDS-PAGE nnd auoradiogra- 
phy yielded ;L single 35 kDa band. The protein was confirmed as 
anncxin V by partial amino acid sequence of cyanogen bro.:ide- 
clcwcd framcnts, PoiyclonaJ anr?;erum to nnlive annexin V was 
raised in rabbits using standard procedures [S]. Monospecific antibody 
was prepdrcd by anncxin V afliuity chromatography followed by 
plasma protein altinity chromatography. 10 ml ofanncxin V affinity 
resin (I mg protein/ml Bio-Rad Affigel I5 resin) was equilibrated with 
20 mM Tris (plH 7.4). 0.15 M N&l. 50 ml of antiserum was applied 
to the column and after extensive washing with the cquilibrdtion 
buffer, baund antiha& was &ted using 0.I M_@cirte<oH 2.51. The 
cluutc was immediately neutralized with a 0.2 vol. of 1 M t&HP& 
and dialyzed overnight against 20 mM Tris (ptl 7.4). 0.15 M N&I. 
To ensure limination ofsmall amounts ofanti-albumin present in the 
antiserum, the cluate was then applied to a column containing normal 
plasma protein coupled to Affigcl 15 (5 rng protein/ml resin). This was 
pcrrormcd essentially as described for the anncxin V affinity step. The 
flow through was collected md conccntratcd by ultraliltration. 
Control IgG was prepared from the llow through of tl:c annexin Y 
Aff~gcl affinity column. IO ml of this material wus applied to a 5 ml 
prolcin G-Sepharose column (Pharmacia). After extensive washing 
with the equilibrdtion bulTer, the IgG was cluted using 0.1 M glycine 
(pH 3.5), immediately neutralized with 1 M KIHPQ and dialytcd a5 
described above. The material was concentrated to 2 mdml by ultraf~l- 
tralion. 
2.2. Ccl~s 
Materials for cell culture were from Flow Laboratories. Human 
endotheliul cells were isolated from umbilical veins ati described [4]. 
Endothclial cells were grown on gclatinizc? (0.1%) plates in Ml99 
medium supplemcntcd with 10% heat-inactivated feral cnlrscrum. The 
human fibroblast cell line, HES. was purchased from Commonwcnlth 
Serum Laboratories (Australia) and the HeLa ccl1 line was a gift from 
Dr. P. Gleeson (Department of Immunology and Pathology, Monash 
Medical School, Alfred Hospital). A549 cells were purchttsrl from 
ATCC. All cell lines were grown in Dulbccco’s modified Eagle’s mc- 
dium and fetal calf serum (10% Y/V). 
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2.3. Fructionotiori of cells 
Cytoplasmic and nuclear extracts were obtained by sequcnlinl cx- 
traction in detergent-containing buffers [IO]. Using this procedure, 
lcakqge of nuclear components into cytoplasmic f’ructions is minimal 
[IO]. Briefly, washed monoluyers were disrupted in situ with a buffer 
containing 0.5% Triton X-100 in order to release cytoplasrnic ompo- 
nents. The resuhing solution (cyloplasmic extract) was collected, nu- 
clei remaining on the dish were washed, then lyscd in a buffer contain- 
ing 0.5% Nonidct P40. Following cenlrifugation at 13,000 x g to 
remove debris, the supcrnalunt (nuclear extract) was collected. 
Indirect immunoiluorcscence was essentially as described [ 111. Cells 
grown on coverslips were fixed in 3.7% formaldehyde and permenbil- 
izcd using 0.1% Triton X-100. In experiments o demonstrate annexin 
V in isolalcd nuclei, cells were trented first with 0.1% Triton X-100 and 
then fixed. For double staining, samples were first ihcttbaied with 
anti-anncxin V antibody (1 p&ml) ior 60 Inin, then washed and incu- 
bated with a sheep anti-rabbit fluorescein isathiouyanate (FITC)-con- 
jugaud second antibody (Silenus, Australia). This was Followed by a 
second 60 min in&&on in a 1:200 dilution. of an autoimmune human 
serum known to conlain anti-nucleo!or antibodies (a Bift from Dr. J. 
Rolland, Department of Immunology nnd Pathology, Monash Uni- 
versity), washing and incuhntion :vith sheep anti-human rhodamine 
isothiocyanate (RlTC)-conjugated second anlibody (Silcnus, Austra- 
lia). Immunoblotdng followLui standard procedures [8] usinB a horse- 
radish peroxidose-conjugated anti-rabbit second antibody and a 4- 
chloro-I-naphtha1 development system (Bio-Rad). 
2.5. Fluorescerrt labeling cwd direct bindhg of annexh V 
200 ,uug of purified annexin V was labeled with FITC as described 
[S]. Cells were fixed in 3.7% formaldehyde and permeabilized using 
0.1% Triton X-100 as described above. In experiments odcmonstrate 
binding of annexin V to nuclei, cells were lreatcd first with 0.1% Triton 
X-100 and then fixed. The FITC-labeled anncxin V (I ,ugIml in 20 mM 
This (pW 7.4), 0.15 M N&I, 1 mM EGTA, 0.1% Triton X-100) was 
incubated with the cells at 37OC overnight. Celis were washed at room 
temperature 3 times (10 min each) in the same solution lacking anncxin 
V, and then 3 times in a modified solution lacking annexin V and 
containing 2 M NaCI. 
3. RESULTS 
3.1. Characterimtion of a monospecific annexin V anti- 
A monospecific anti-annexin V antibody was pre- 
pared by chromatography of rabbit antiserum on a col- 
umn containing immobilized, pure annexin V. Western 
blotting was used to determine the specificity of the 
anti-annexin V antibody. The crude antiserum recog- 
nised two proteins in a partially pure preparation of 
annexin V known to contain albumin, and several pro- 
teins in plasma (Fig. 1). On the other hand, the antibody 
eluted from the annexin V affinity column reacted with 
only one protein in the semi-purified annexin V prepa- 
ration, and showed no detectable reactivity with pro- 
teins in plasma (Fig. 1). Further analysis revealed that 
the antibody reacted with a single 35 kDa protein in 
total protein extracts prepared from endothelial cells 
and fibroblasts (data not shown). Although annexin V 
is structurally similar to other members of the annexin 
family, these results show that the purified antibodies 





Fig. 1. Monospecificity of anti-anncxin V antibodies. Samples were 
scoarated on 10% SDS-PAGE acls and lransferred to nitrocellulose. 
Mimbrones were probLti with; I:200 difution of the crude rnbbii 
and-annexin antiserum (lanes I und 2) or 2 ,udml affinity-purified 
anti-anncxin antibodies {lanes 3 and 4). Target antigens were 10 lug 
partially purified annexin V (lanes 1 and 3) and 100,~ normal human 
plasma protein (lanes 2 and 4). 
3.2. Cellular locahkatiort of annexin V 
The distribution of annexin V in human endothelial 
cells was studied using the monospecific antibody in an 
indirect immunofluorescence assay. Annexin V was not 
cletectcd on the endothelial cell surface (Fig. 2a), how- 
ever, when the cells were permeabi!ized with 0.1% Tri- 
ton X-100, positive staining was observed in the cyto- 
plasm and nucleus (Fig. 2b). No staining was obsrrved 
using a control antibody (data not shown). Similar re- 
sults Were obtained using human HES, HeLa and A549 
cells, as well as with several mouse and simian lines 
(data not shown). 
The bright cytoplasmic fluorescence obscured nu- 
clear details and made it difficult to accurately deter- 
mine the nuclear distribution of anncxin V. To over- 
come this problem, endothelial cells attached to cov- 
erslips were treated with lysis buffer, gently washed, 
then fixed. This served to lyse the ce!ls without affecting 
nuclear structures. ‘Nuclei prepared in this way and 
treated with the anti-annexin V antibody revealed a 
nucleolar pattern of staining (Fig. 2~). To confirm this 
nucleolar distribution a double-staining procedure was 
used in which nuclei were treated first with the anti- 
annexin V antibody and a fluorescein-conjugated sec- 
ond antibody (Fig. 2c), and then with antiserum con- 
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Fig. 2. Intracellular localization of annexin V. Intact (a) or pcrmcabilizcd (b) endothclial cells wcrc stained using 1 ygfml au&am&n V as tbc 
first nntiboilj and a I:200 dilution of a FITC-conjugated anti-rabbit IgG as the sczond nnribody. Endothclial cell nuclei (c,d) wcrc first stained 
as described for a and b, und then were stained with a I:200 dilution oT human anti-nucleolar antiserum and a I:200 dilution of a RlTGconjugatd 
anti-human IgG. Panel c shows nuclei marked with FITC (annexin), and panel d shows the same nuclei marked with RITC (nuclcolar). There was 
no cross-reaction observed bctwcen the antibodies (not shown). 
taining anti-nucleolar antibodies and a rhodamine-con- 
jugatcd second antibody (Fig. 2d). Co-localization of 
the annexin V and nucleolar antibodies was observed, 
confirming the nucleolar distribution of annexin V. 
The subcellular distribution of annexin V was also 
studied by preparing crude cytoplasmic and nuclear ex- 
tracts from endothelial and HES cells and immunoblot- 
ting using the monospecific antibody (Fig. 3). A 35 kDa 
protein was present in all of the extracts, which is con- 
sistent with the distribution of annexin V obselred using 
indirect immunofluorescence. 
To confirm the intracellular distribution of annexin 
V and to assess the role of calcium in the compartmen- 
talization ofannexin V, direct binding experiments were 
carried out. Fluorescently labeled annexin V was incu- 
bated with fixed and permeabilized cells or nuclei in a 
solution lacking calcium and containing ECTA (Fig. 4). 
A similar staining pattern to that obtained using anti- 
annexin V antibodies was observed. Addition of 2.5 
mM calcium to the binding solution did not signifi- 
cantiy aiter the distribulion of annexin V, -whereas the 
inclusion of unlabeled annexin V in loo-fold excess ab- 
rogated staining (data not shown). 
4. DISCUSSION 
The annexin gene superfamily presently contains over 
I3 members, most of which show restricted species or 
tissue distribution. Although the annexins share the 
property of calcium-dependent phospholipid binding, 
specific physiological functions have been ascribed to 
only three. These are annexin II, which participates in 
calcium-dependent exocytosis [121; annexin III, which 
is an inositol 1 ,Zcyclic phosphate 2-phosphohydrolase 
[13]; and annexin VI, which is required for the budding 
of clathrin-coated endocytic pits [14]. 
The structure, function and tissue distribution of an- 
nexin V has been studied in some detail, yet its physio- 
logical role is unclear. Our studies, using both anti- 
annexin V antibodies and a direct binding approach, 
show that annexin V can be found in the cytoplasm. 
Due to the limitations of the immunoRuorescence and 
fractionation techniques, at present we cannot rule out 
an association of annexin V with the cytoskeleton or 
with cytoplasmic organelles uch as mitochondria. An- 
nexin V is, however, clearly present in the nucleolus. 
CLILllUYgll LC ,0 SILlY&I cnvrp.. . A 1*1--a* h :C :c m-11 D naarrh +o rliflnaom ;ntn thp s~gc!cr_rs, “...““W ....” 
the retention of annexin V in the nucleolus probably 
requires a specific mechanism. For example, it may re- 
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Fig. 3. Anncxin V in cytosolic and nuclear fractions from endothelial 
cells and fibroblasts. Extracts containing 50 yg of protein were sepa- 
rated on 10% SDS-PAGE gels and transferred to nitrocellulosc. The 
membmnc was probed using the monospecific anti-unncxin V anti- 
body (2 r&ml) and a HRP-conjugntcd second antibody (1:400). Lane 
1, annexin V, 0.2 Jrg; lane 2. endothelial cell cytosolic extract; lane 3, 
cytosolic extract from HES cells; lane 4, cndotheliol cell nuclear cx- 
tract: lane 5, nuclear extract from HES cells. 
Fig. 4. Binding of annexin V to cells and nuclei. Pemmbilkd A549 
cells (a) or nuclei (b) were stained with I @ml FITC-conjuguted 
anncxin V in the absence of calcium. 
quire nucleic acid binding ability, as recently demon- 
strated for the nucleolar transcription factor, mUBF 
[ 151. Interestingly, we have observed that annexin V can 
bind to DNA (unpublished results). 
Recently, Mizutani et al. have reported that a new 50 
kDa annexin (CAP 50) localizes in the nuclei (but not 
nucleoli) of 3Y 1 fibroblasts in a calcium-dependent 
manner [lG]. The distribution of annexil:! V we observed 
occurs in the presence of detergent and in the absence 
of calcium, suggesting that the compartmentalization of
annexin V between cytoplasm and nucleus probably 
does not depend on binding to phospholipid. 
The demonstration that two different annexins local- 
ize to the nucleus raises the prospect hat annexins may 
contribute to processes that are fundamental for cell 
growth or division. Annexin V is found in the nucleolus, 
which is the most obvious structure contained in the 
nucleus of a non-mitotic cell. As the only known nucle- 
alar function is the synthesis of ribosomal RNA and the 
assembly of ribosomes, it is possible that annexin V is 
involved in either the establishment and maintenance of 
nucleolar structure or in ribosome synthesis, assembly, 
transport and function. Either role would probably be 
important for cell growth and survival, but our finding 
that annexin V is also present in the cytoplasm is more 
consistent with a contribution to ribosome biosynthesis 
or function. 
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